102 Then again, many groups are advocating for that incorporation of novel markers, such as a advanced karyotype55 or epigenetic subsets, 27,28 into clinical apply. All these novel prognostic and/or predictive products will have to be validated in cohorts of patients taken care of with qualified agents.Some degree of immunophenotype overlap among t